Sugi Predict

Sugi Predict / Compounds / SCHEMBL259496

SCHEMBL259496

SCHEMBL259496

CNC(=O)c1ccc(N)nc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 3/20 0.70
▸ HDAC1 Q13547 2/20 0.70
▸ SMN1; SMN2 Q16637 2/20 0.60
▸ NNMT P40261 2/20 0.60
▸ GABRP O00591 1/20 0.60
▸ GABRD O14764 1/20 0.60
▸ GABRA1 P14867 1/20 0.60
▸ GABRB1 P18505 1/20 0.60
▸ GABRG2 P18507 1/20 0.60
▸ GABRB3 P28472 1/20 0.60
▸ GABRA5 P31644 1/20 0.60
▸ GABRA3 P34903 1/20 0.60
▸ GABRA2 P47869 1/20 0.60
▸ GABRB2 P47870 1/20 0.60
▸ GABRA4 P48169 1/20 0.60
▸ GABRE P78334 1/20 0.60
▸ GABRA6 Q16445 1/20 0.60
▸ GABRG1 Q8N1C3 1/20 0.60
▸ GABRG3 Q99928 1/20 0.60
▸ GABRQ Q9UN88 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8483127 0.82 HDAC1 (0.72) HDAC6HDAC1SMN1; SMN2NNMTGABRP
SCHEMBL11324381 0.82 HDAC6 (1.00) HDAC6HDAC1SMN1; SMN2NNMTGABRP
SCHEMBL12749174 0.82 SMN1; SMN2 (0.67) HDAC6HDAC1SMN1; SMN2NNMTGABRP
SCHEMBL14067467 0.81 HDAC1 (0.70) HDAC6HDAC1SMN1; SMN2NNMTGABRP
SCHEMBL2988703 0.81 HDAC1 (0.70) HDAC6HDAC1SMN1; SMN2NNMTGABRP
SCHEMBL11982165 0.80 HDAC1 (0.64) HDAC6HDAC1SMN1; SMN2NNMTGABRP
SCHEMBL853202 0.80 HDAC1 (0.64) HDAC6HDAC1SMN1; SMN2NNMTGABRP
SCHEMBL17055207 0.80 HDAC1 (0.64) HDAC6HDAC1SMN1; SMN2NNMTGABRP
SCHEMBL7962334 0.80 BAZ2B (0.74) HDAC6HDAC1SMN1; SMN2BAZ2BGRM5
SCHEMBL13184552 0.78 BAZ2B (0.57) HDAC6HDAC1SMN1; SMN2BAZ2BGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114262609-B Autoflash fluorescent dye for long-time super-resolution fluorescent imaging of lysosomes as well as synthesis method and application thereof 中国科学院大连化学物理研究所 2024-10-22 — — CN disclosed
US-11957683-B2 Bicyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2024-04-16 — — US disclosed
CN-111542523-B Heterocyclic compounds as PRMT5 inhibitors 朱比连特埃皮斯科瑞有限责任公司 2024-03-29 — — CN disclosed
EP-3704120-B1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS JUBILANT EPISCRIBE LLC (US) 2024-03-06 — — EP disclosed
CN-114262334-B Super-resolution imaging autoflash fluorescent dye for monitoring lysosome dynamic in real time under nanometer resolution, and synthetic method and application thereof 中国科学院大连化学物理研究所 2023-07-04 — — CN disclosed
CN-114262335-B Super-resolution self-flashing dye of targeting lysosome, and synthetic method and biological application thereof 中国科学院大连化学物理研究所 2023-07-04 — — CN disclosed
US-20230065217-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS ESCIENT PHARMACEUTICALS, INC. 2023-03-02 — — US disclosed
US-20230051483-A1 BICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2023-02-16 — — US disclosed
WO-2022266193-A1 BICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2022-12-22 — — WO disclosed
US-11459338-B2 Heterocyclic compounds as PRMT5 inhibitors JUBILANT EPISCRIBE LLC (US) 2022-10-04 — — US disclosed
US-20080153821-A1 Nitrogen-containing 5-membered ring compound TANABE SEIYAKU CO., LTD. 2008-06-26 — — US disclosed
US-20080096882-A1 PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-04-24 — — US disclosed
US-7332487-B2 Nitrogen-containing 5-membered ring compound TANABE SEIYAKU CO., LTD. (JP) 2008-02-19 — — US disclosed
WO-2007118793-A1 DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-25 — — WO disclosed
WO-2007095188-A2 DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-08-23 — — WO disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 — — US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 — — US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 — — US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 — — US disclosed
US-4647569-A Antiarthritic pyridylaminoethene disulfonyl compounds and use MAY & BAKER LIMITED (GB) 1987-03-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230065217-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS MRGPRX2, MRGPRX1, MRGPRX4 HDAC6 2604/4885HDAC1 2175/4885SMN1; SMN2 4471/4885
US-20230051483-A1 BICYCLIC COMPOUNDS SLC10A1, PKD1, CYP11B2 HDAC6 16/4885HDAC1 42/4885SMN1; SMN2 611/4885
US-20080096882-A1 PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system PDE4A, PDE4B, PDE12 HDAC6 1243/4885HDAC1 846/4885SMN1; SMN2 1736/4885
US-11459338-B2 Heterocyclic compounds as PRMT5 inhibitors PRMT5, PRMT1, PRMT3 HDAC6 319/4885HDAC1 77/4885SMN1; SMN2 972/4885
US-11957683-B2 Bicyclic compounds SLC10A1, PKD1, CYP11B2 HDAC6 16/4885HDAC1 42/4885SMN1; SMN2 611/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A HDAC6 191/4885HDAC1 193/4885SMN1; SMN2 4764/4885
US-20080153821-A1 Nitrogen-containing 5-membered ring compound ALK, SCO2, NPR1 HDAC6 601/4885HDAC1 1398/4885SMN1; SMN2 759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.